Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edesa Biotech Inc (NQ: EDSA )

2.210 +0.040 (+1.84%)
Streaming Delayed Price Updated: 1:02 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Edesa Biotech Inc

< Previous 1 2 3 Next >
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS
Via ACCESSWIRE
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
Via ACCESSWIRE
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
Via ACCESSWIRE
Edesa Biotech to Participate in Upcoming Investor Conferences
Via ACCESSWIRE
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
Via ACCESSWIRE
Edesa Biotech to Participate in Barclays Global Healthcare Conference
Via ACCESSWIRE
Edesa Biotech to Participate in Upcoming Dermatology Meetings
Via ACCESSWIRE
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
Via ACCESSWIRE
Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
Via ACCESSWIRE
Edesa Biotech Reports Fiscal Year 2023 Results
Via ACCESSWIRE
Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
Via ACCESSWIRE
Edesa Biotech to Present at Dermatology Drug Development Summit
Via ACCESSWIRE
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS Drug
Via ACCESSWIRE
Edesa Biotech Secures $10 Million Credit Facility with Company Founder
Via ACCESSWIRE
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
Via ACCESSWIRE
Edesa Biotech Announces One-for-Seven Reverse Share Split
Via ACCESSWIRE
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
Via ACCESSWIRE
Edesa Biotech Reports Fiscal Third Quarter 2023 Results
Via ACCESSWIRE
Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference
Via ACCESSWIRE
Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
Via ACCESSWIRE
Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
Via ACCESSWIRE
Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results
Via ACCESSWIRE
Edesa Biotech to Participate in Swiss Biotech Day
Via ACCESSWIRE
The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate
Via ACCESSWIRE
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference
Via ACCESSWIRE
Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting
Via ACCESSWIRE
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
Via ACCESSWIRE
Edesa Biotech Reports Fiscal 1st Quarter 2023 Results
Via ACCESSWIRE
Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
Via ACCESSWIRE
Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug
Via ACCESSWIRE
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.